Details of the Drug

General Information of Drug (ID: DMK7MEY)

Drug Name
Isoproterenol
Synonyms
isoproterenol; Isoprenaline; Isoprenalin; Norisodrine; Novodrin; Isopropydrin; Isopropylarterenol; Respifral; Assiprenol; Asiprenol; Bellasthman; Asmalar; Aludrine; Aludrin; N-Isopropylnoradrenaline; Bronkephrine; Neodrenal; Lomupren; Isonorene; Isopropyladrenaline; 7683-59-2; N-Isopropylnorepinephrine; Isopropylnorepinephrine; neo-Epinine; Isadrine; Saventrine; Isorenin; Isonorin; Proternol; Isopropylnoradrenaline; Isopropyl noradrenaline; Racemic isoprenaline; dl-Isadrine; Racemic isoproterenol; (+-)-Isoproterenol; Vapo-N-iso; Aerolone; Aleudrine; Dihydroxyphenylethanolisopropylamine; Euspiran; ISOPROP; Isadrin; Isoproterenolum; Isuprel; Isupren; Izadrin; Epinephrine isopropyl homolog; Isoprenaline hydrochloride; Isoproterenol Chloride; Isoproterenol [JAN]; Isuprel Mistometer; WIN 5162; D-Isoprenaline; D-Isopropylarterenol; D-Isoproterenol; DL-Isopropylnorepinephrine; Dl-Ipr; Dl-Isadrine; Dl-Isopropylnoradrenaline; Isoprenalina [INN-Spanish]; Isoprenaline (INN); Isoprenalinum [INN-Latin]; Isuprel (TN); L-Isopropylnoradrenaline; L-Isoproterenol; Medihaler-ISO; Neo-Epinine; Vapo-Iso; Alpha-(Isopropylaminomethyl)protocatechuyl alcohol; Alpha-(Isopropylaminomoethyl)protocatechuyl alcohol; D-N-Isopropylnorepinephrine; Dl-N-Isopropylnoradrenaline; Isopropylaminomethyl(3,4-dihydroxyphenyl)carbinol; Isopropylaminomethyl-3,4-dihydroxyphenyl carbinol; DL(+-)-Isoproterenol; N-Isopropyl-beta-dihydroxyphenyl-beta-hydroxyethylamine; (+)-Isoprenaline; (+)-Isoproterenol; (+-)-Isoprenaline; (-)-Isoproterenol hydrochloride; (S)-(+)-Isoproterenol; (S)-Isoprenaline; (S)-Isoproterenol; 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-(9CI); 1,2-Benzenediol, 4-(1-hydroxy-2-((1-methylethyl)amino)ethyl)-, (S)-(9CI); 1-(3,4-Dihydroxyphenyl)-2-(isopropylamino)ethanol; 1-(3,4-Dihydroxyphenyl)-2-isopropylaminoethanol; 3,4-Dihydroxy-alpha-(isopropylaminomethyl)-benzyl alcohol; 3,4-Dihydroxy-alpha-[(isopropylamino)methyl]benzyl alcohol; 3,4-Dihydroxy-alpha-((isopropylamino)methyl)benzyl alcohol; 4-(1-Hydroxy-2(isopropylamino)ethyl)-benzene 1,2-diol; 4-(1-Hydroxy-2-((1-methylethyl)amino)ethyl)-1,2-benzenediol; 4-{1-hydroxy-2-[(1-methylethyl)amino]ethyl}benzene-1,2-diol; AS1409
Indication
Disease Entry ICD 11 Status REF
Heart block BC63 Approved [1]
Melanoma 2C30 Phase 1 [2]
Therapeutic Class
Cardiotonic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 211.26
Topological Polar Surface Area (xlogp) -0.6
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 4
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
Clearance
The clearance of drug is 42.5 +/- 5.0 mL/min/kg [3]
Elimination
Isoprenaline is 12.2-27.0% recovered in the feces and 59.1-106.8% recovered in the urine after 48 hours [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 - 5 minutes [5]
Metabolism
The drug is metabolized via renal [4]
Vd
The volume of distribution (Vd) of drug is 0.216 L/kg [3]
Chemical Identifiers
Formula
C11H17NO3
IUPAC Name
4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol
Canonical SMILES
CC(C)NCC(C1=CC(=C(C=C1)O)O)O
InChI
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3
InChIKey
JWZZKOKVBUJMES-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3779
ChEBI ID
CHEBI:64317
CAS Number
7683-59-2
DrugBank ID
DB01064
TTD ID
D0I8FI
INTEDE ID
DR0887
ACDINA ID
D01182

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Agonist [6]
Adrenergic receptor beta-2 (ADRB2) TT2CJVK ADRB2_HUMAN Modulator [6], [7]
Interleukin-12 beta (IL12B) TTGW72V IL12B_HUMAN Modulator [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Thiopurine methyltransferase (TPMT)
Main DME 		DEFQ8VO TPMT_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Heart block
ICD Disease Classification BC63
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-12 beta (IL12B) DTT IL12B 9.01E-01 1.32E-02 0.07
Thiopurine methyltransferase (TPMT) DME TPMT 1.02E-02 -4.35E-01 -1.68E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Isoproterenol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Moderate Additive hypertensive effects by the combination of Isoproterenol and Methylene blue. Acquired methaemoglobinaemia [3A93] [41]
Ivosidenib DM8S6T7 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Ivosidenib. Acute myeloid leukaemia [2A60] [42]
Midostaurin DMI6E0R Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Midostaurin. Acute myeloid leukaemia [2A60] [43]
Idarubicin DMM0XGL Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Idarubicin. Acute myeloid leukaemia [2A60] [43]
Gilteritinib DMWQ4MZ Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Gilteritinib. Acute myeloid leukaemia [2A60] [43]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Oliceridine. Acute pain [MG31] [43]
Ivabradine DM0L594 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Ivabradine. Angina pectoris [BA40] [43]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Isoproterenol and Bepridil. Angina pectoris [BA40] [42]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Isoproterenol and Dronedarone. Angina pectoris [BA40] [42]
Bedaquiline DM3906J Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [42]
Cilostazol DMZMSCT Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Cilostazol. Arterial occlusive disease [BD40] [43]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Posaconazole. Aspergillosis [1F20] [43]
Budesonide DMJIBAW Minor Increased risk of hypokalemia by the combination of Isoproterenol and Budesonide. Asthma [CA23] [44]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [43]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Isoproterenol and Droxidopa. Autonomic nervous system disorder [8D87] [45]
Ofloxacin DM0VQN3 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Ofloxacin. Bacterial infection [1A00-1C4Z] [43]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Clarithromycin. Bacterial infection [1A00-1C4Z] [43]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Isoproterenol and Sparfloxacin. Bacterial infection [1A00-1C4Z] [42]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Gemifloxacin. Bacterial infection [1A00-1C4Z] [43]
Levofloxacin DMS60RB Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Levofloxacin. Bacterial infection [1A00-1C4Z] [43]
Retigabine DMGNYIH Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Retigabine. Behcet disease [4A62] [43]
Eribulin DM1DX4Q Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Eribulin. Breast cancer [2C60-2C6Y] [43]
Lapatinib DM3BH1Y Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Lapatinib. Breast cancer [2C60-2C6Y] [43]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Bosutinib. Breast cancer [2C60-2C6Y] [43]
Corticotropin DMP9TWZ Minor Increased risk of hypokalemia by the combination of Isoproterenol and Corticotropin. Chronic kidney disease [GB61] [44]
PF-04449913 DMSB068 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [43]
Levomilnacipran DMV26S8 Moderate Increased risk of rapid heart rate by the combination of Isoproterenol and Levomilnacipran. Chronic pain [MG30] [46]
Halothane DM80OZ5 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Halothane. Corneal disease [9A76-9A78] [43]
Sevoflurane DMC9O43 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Sevoflurane. Corneal disease [9A76-9A78] [43]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Probucol. Coronary atherosclerosis [BA80] [43]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Isoproterenol and Pasireotide. Cushing syndrome [5A70] [42]
Osilodrostat DMIJC9X Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Osilodrostat. Cushing syndrome [5A70] [43]
Sertraline DM0FB1J Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Sertraline. Depression [6A70-6A7Z] [43]
Isocarboxazid DMAF1NB Moderate Additive hypertensive effects by the combination of Isoproterenol and Isocarboxazid. Depression [6A70-6A7Z] [41]
Milnacipran DMBFE74 Moderate Additive hypertensive effects by the combination of Isoproterenol and Milnacipran. Depression [6A70-6A7Z] [46]
Desvenlafaxine DMHD4PE Moderate Additive hypertensive effects by the combination of Isoproterenol and Desvenlafaxine. Depression [6A70-6A7Z] [46]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [43]
Deutetrabenazine DMUPFLI Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Deutetrabenazine. Dystonic disorder [8A02] [43]
Ingrezza DMVPLNC Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Ingrezza. Dystonic disorder [8A02] [43]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Solifenacin. Functional bladder disorder [GC50] [43]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Sunitinib. Gastrointestinal stromal tumour [2B5B] [43]
Procarbazine DMIK367 Moderate Additive hypertensive effects by the combination of Isoproterenol and Procarbazine. Hodgkin lymphoma [2B30] [41]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Isoproterenol and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [42]
Lopinavir DMITQS0 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [43]
Rilpivirine DMJ0QOW Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [43]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Isoproterenol and Crizotinib. Lung cancer [2C25] [42]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Isoproterenol and Ceritinib. Lung cancer [2C25] [42]
Osimertinib DMRJLAT Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Osimertinib. Lung cancer [2C25] [42]
Selpercatinib DMZR15V Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Selpercatinib. Lung cancer [2C25] [42]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Isoproterenol and Halofantrine. Malaria [1F40-1F45] [42]
Hydroxychloroquine DMSIVND Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Hydroxychloroquine. Malaria [1F40-1F45] [43]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Primaquine. Malaria [1F40-1F45] [43]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [43]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Arsenic trioxide. Mature B-cell lymphoma [2A85] [42]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Isoproterenol and Vemurafenib. Melanoma [2C30] [42]
LGX818 DMNQXV8 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and LGX818. Melanoma [2C30] [43]
Panobinostat DM58WKG Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Panobinostat. Multiple myeloma [2A83] [42]
Siponimod DM2R86O Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Siponimod. Multiple sclerosis [8A40] [43]
Fingolimod DM5JVAN Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Fingolimod. Multiple sclerosis [8A40] [43]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Ozanimod. Multiple sclerosis [8A40] [47]
Romidepsin DMT5GNL Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Romidepsin. Mycosis fungoides [2B01] [43]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Isoproterenol and Nilotinib. Myeloproliferative neoplasm [2A20] [42]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Dasatinib. Myeloproliferative neoplasm [2A20] [43]
Promethazine DM6I5GR Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Promethazine. Nausea/vomiting [MD90] [43]
Entrectinib DMMPTLH Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Entrectinib. Non-small cell lung cancer [2C25] [43]
Sibutramine DMFJTDI Moderate Increased risk of rapid heart rate by the combination of Isoproterenol and Sibutramine. Obesity [5B80-5B81] [48]
Levomethadyl Acetate DM06HG5 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Levomethadyl Acetate. Opioid use disorder [6C43] [42]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Rucaparib. Ovarian cancer [2C73] [43]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Triclabendazole. Parasitic worm infestation [1F90] [43]
Safinamide DM0YWJC Moderate Additive hypertensive effects by the combination of Isoproterenol and Safinamide. Parkinsonism [8A00] [41]
Opicapone DM1BKA6 Moderate Decreased metabolism of Isoproterenol caused by Opicapone mediated inhibition of non-CYP450 enzyme. Parkinsonism [8A00] [49]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Isoproterenol and Rasagiline. Parkinsonism [8A00] [41]
Pimavanserin DMR7IVC Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Pimavanserin. Parkinsonism [8A00] [43]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Isoproterenol and Macimorelin. Pituitary gland disorder [5A60-5A61] [50]
Lefamulin DME6G97 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Lefamulin. Pneumonia [CA40] [42]
Degarelix DM3O8QY Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Degarelix. Prostate cancer [2C82] [43]
ABIRATERONE DM8V75C Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and ABIRATERONE. Prostate cancer [2C82] [43]
Enzalutamide DMGL19D Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Enzalutamide. Prostate cancer [2C82] [43]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Relugolix. Prostate cancer [2C82] [43]
Bicalutamide DMZMSPF Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Bicalutamide. Prostate cancer [2C82] [43]
Levomepromazine DMIKFEL Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Levomepromazine. Psychotic disorder [6A20-6A25] [43]
Ciclesonide DM2NA4K Minor Increased risk of hypokalemia by the combination of Isoproterenol and Ciclesonide. Respiratory system disease [CB40-CB7Z] [44]
Dexamethasone DMMWZET Minor Increased risk of hypokalemia by the combination of Isoproterenol and Dexamethasone. Rheumatoid arthritis [FA20] [44]
Quetiapine DM1N62C Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Quetiapine. Schizophrenia [6A20] [43]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Aripiprazole. Schizophrenia [6A20] [44]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Isoproterenol and Iloperidone. Schizophrenia [6A20] [42]
Paliperidone DM7NPJS Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Paliperidone. Schizophrenia [6A20] [43]
Amisulpride DMSJVAM Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Amisulpride. Schizophrenia [6A20] [42]
Asenapine DMSQZE2 Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Asenapine. Schizophrenia [6A20] [43]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Isoproterenol and LEE011. Solid tumour/cancer [2A00-2F9Z] [51]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Isoproterenol and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [42]
Triptorelin DMTK4LS Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [43]
Pitolisant DM8RFNJ Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Pitolisant. Somnolence [MG42] [43]
Telavancin DM58VQX Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [43]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Lenvatinib. Thyroid cancer [2D10] [43]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Isoproterenol and Cabozantinib. Thyroid cancer [2D10] [42]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Isoproterenol and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [43]
Fluticasone DMGCSVF Minor Increased risk of hypokalemia by the combination of Isoproterenol and Fluticasone. Vasomotor/allergic rhinitis [CA08] [44]
Propafenone DMPIBJK Moderate Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Propafenone. Ventricular tachyarrhythmia [BC71] [43]
Amiodarone DMUTEX3 Major Increased risk of ventricular arrhythmias by the combination of Isoproterenol and Amiodarone. Ventricular tachyarrhythmia [BC71] [42]
⏷ Show the Full List of 100 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Hydrochloric acid E00015 313 Acidulant
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium citrate anhydrous E00102 6224 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Edetate disodium E00186 8759 Complexing agent
Nitrogen E00033 947 Aerosol propellant; Sparging agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium citrate dihydrate E00369 71474 Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium hydroxide E00234 14798 Alkalizing agent
Water E00035 962 Solvent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Isoproterenol 1mg/5ml solution 1mg/5ml Solution Intracardiac; Intramuscular; Intravenous; Subcutaneous
Isoproterenol 1mg/5ml solution 1mg/5ml Solution Intravenous; Intramuscular; Subcutaneous; Intracardiac
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 083346.
2 A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
3 Reyes G, Schwartz PH, Newth CJ, Eldadah MK: The pharmacokinetics of isoproterenol in critically ill pediatric patients. J Clin Pharmacol. 1993 Jan;33(1):29-34. doi: 10.1002/j.1552-4604.1993.tb03899.x.
4 Klimas R, Mikus G: Morphine-6-glucuronide is responsible for the analgesic effect after morphine administration: a quantitative review of morphine, morphine-6-glucuronide, and morphine-3-glucuronide. Br J Anaesth. 2014 Dec;113(6):935-44. doi: 10.1093/bja/aeu186. Epub 2014 Jul 1.
5 Isoproterenol .
6 Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma. Clin Cancer Res. 2011 Apr 1;17(7):1998-2005.
9 Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol. 2011 Mar;102(1-2):18-23.
10 Genetics of rheumatoid arthritis. Mayo Clin Proc. 2006 Jan;81(1):94-101.
11 Polymorphism of estrogen metabolism genes and cataract. Med Hypotheses. 2004;63(3):494-7.
12 Influence of estradiol-17 beta and progesterone on catechol-O-methyltransferase and monoamine oxidase activities in uterine artery and myometrium of ovariectomized pigs. Arch Vet Pol. 1993;33(1-2):29-37.
13 The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse. Leukemia. 2010 Apr;24(4):715-20.
14 Histamine-N-methyl transferase polymorphism and risk for multiple sclerosis. Eur J Neurol. 2010 Feb;17(2):335-8.
15 Ascorbic acid inhibits spinal meningeal catechol-o-methyl transferase in vitro, markedly increasing epinephrine bioavailability. Anesthesiology. 1997 Feb;86(2):405-9.
16 Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8.
17 Adrenal catecholamines and their metabolism in the vitamin A deficient rat. Ann Nutr Metab. 1983;27(3):220-7.
18 Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet. 2010 Mar 5;153B(2):542-548.
19 Usefulness of thiopurine methyltransferase and thiopurine metabolite analysis in clinical practice in patients with inflammatory bowel diseases. Acta Gastroenterol Belg. 2010 Jul-Sep;73(3):331-5.
20 Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
21 Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
22 Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
23 Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
24 Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
25 beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
26 beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
27 Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
28 Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
29 Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
30 Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
31 Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
32 Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
33 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
34 Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
35 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
36 Briakinumab for the treatment of plaque psoriasis.BioDrugs.2012 Feb 1;26(1):9-20.
37 National Cancer Institute Drug Dictionary (drug id 454593).
38 Clinical pipeline report, company report or official report of Trademarkia.
39 National Cancer Institute Drug Dictionary (drug id 710508).
40 The immunocytokine NHS-IL12 as a potential cancer therapeutic. Oncotarget. 2014 Apr 15;5(7):1869-84.
41 Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5. [PMID: 4685619]
42 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
43 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
44 Cerner Multum, Inc. "Australian Product Information.".
45 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
46 Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
47 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
48 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
49 Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther 58 (1995): 221-7. [PMID: 7648772]
50 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
51 Canadian Pharmacists Association.